KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Short term Debt (2016 - 2025)

Jazz Pharmaceuticals has reported Short term Debt over the past 16 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Short term Debt at $1.0 billion for Q4 2025, up 3222.27% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (up 3222.27% YoY), and the annual figure for FY2025 was $1.0 billion, up 3222.27%.
  • Short term Debt for Q4 2025 was $1.0 billion at Jazz Pharmaceuticals, roughly flat from $1.0 billion in the prior quarter.
  • Over the last five years, Short term Debt for JAZZ hit a ceiling of $1.0 billion in Q4 2025 and a floor of $31.0 million in Q3 2021.
  • Median Short term Debt over the past 5 years was $31.0 million (2021), compared with a mean of $317.3 million.
  • Peak annual rise in Short term Debt hit 3222.27% in 2025, while the deepest fall reached 94.88% in 2025.
  • Jazz Pharmaceuticals' Short term Debt stood at $31.0 million in 2021, then changed by 0.0% to $31.0 million in 2022, then soared by 1851.46% to $605.0 million in 2023, then crashed by 94.88% to $31.0 million in 2024, then soared by 3222.27% to $1.0 billion in 2025.
  • The last three reported values for Short term Debt were $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.